Chu X, Hong Y, Wang Y, et al. - In antineutrophil cytoplasmic antibody-associated vasculitis (AAV) patients with severe kidney involvement, a quicker and higher remission and lower mortality were shown to be conferred by immunoadsorption (IA) treatment. For these patients, early remission is an independent predictor of the outcomes.

• This is a retrospective analysis of clinical data of 60 patients with AAV and severe kidney involvement.

• Patients were treated with cyclophosphamide or rituximab for remission induction, of which 16 additionally received IA.

• Post-induction treatment, a more obvious reduction in disease activity was seen in the IA group vs the control group.

• Following a median follow-up of 20.2 months, the IA group had more quick and higher remission (hazard ratio (HR) = 2.3) than the control group.

• IA therapy conferred a benefit in decreasing death (HR = 0.2).

• Early-stage remission was identified to be an independent predictor for end-stage kidney disease (HR = 0.03) and death (HR = 0.07).